Shares of oncology firm Verastem, Inc. have recently experienced a significant downturn, dropping approximately 40% since reaching a 16-month high in September 2025. This decline is attributed to several hurdles encountered by its newly approved therapy, Avmapki Fakzynja (AF co-pack), particularly concerning its label expansion prospects. Despite a recent accelerated approval for KRAS mutant Low-Grade Serous Ovarian Cancer (LGSOC), the company faces challenges that have impacted investor confidence.

The current U.S. market for AF co-pack in its approved indication is estimated to be around $2.6 billion, with a potential for peak sales reaching $750 million. However, the path to expanding its use into other areas has been fraught with difficulties. Modifications to its clinical trials and delays in achieving new indications have raised concerns among analysts and investors alike.

A significant development is the expansion of the RAMP 301 trial, which now includes an additional 29 patients, bringing the total to 299. This adjustment aims to bolster the trial's statistical power, increasing the likelihood of demonstrating significant improvements in progression-free survival and overall survival endpoints. A successful outcome from this pivotal trial is critical, as it would pave the way for regulatory submissions in Europe and Japan, potentially unlocking new revenue streams and market opportunities. The eagerly anticipated results from the RAMP 301 trial are expected in mid-2027.

Investors are closely monitoring Verastem's progress, recognizing that the success of AF co-pack hinges on these upcoming trial readouts and the company's ability to navigate the complex regulatory landscape for label expansion. The future trajectory of Verastem’s stock will largely depend on the positive outcomes from its ongoing clinical development programs.